The “Targeted Protein Degradation Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade.
To order this 330+page report, please visit this link
Key Inclusions
§ A detailed assessmentof the current market landscape of targeted protein degradation-basedtherapeutics, providing information on drug / therapy developer(s) (such asyear of establishment, company size and location of headquarters), clinicalstudy sponsor(s) and collaborator(s), type of protein degrader (degronimids,ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecularglues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs,and specific BET and DUB inhibitors), phase of development (clinical,preclinical, and discovery stage) of product candidates, target indication(s),key therapeutic area(s), type of target protein(s), target enzyme(s) (ifavailable), target signaling pathway (if available), mechanism ofaction (if available), type of therapy (monotherapy and combinationtherapy), route of administration (oral, intravenous and others), andinformation on special drug designations (if any). In addition, thechapter highlights the various technology platforms that are being activelyused for the development of targeted protein degraders.
§ Elaborate profiles ofkey players that are engaged in the development of targeted protein degraders (shortlistedon the basis of phase of development of pipeline products), featuring abrief overview of the company, its financial information (if available),detailed descriptions of their respective lead drug candidates, and an informedfuture outlook. Additionally, each drug profile features information on thetype of drug, route of administration, target indications, current status ofdevelopment and a brief summary of its developmental history.
§ Brief tabulatedprofiles of industry players (shortlisted on the basis of the number ofpipeline products), featuring details on the innovator company (such asyear of establishment, location of headquarters, number of employees, and keymembers of the executive team), recent developments, along with descriptions oftheir respective drug candidates.
§ A detailed clinicaltrial analysis of completed, ongoing and planned studies of various targetedprotein degraders, highlighting prevalent trends across various relevantparameters, such as current trial status, trial registration year, enrolledpatient population and regional distribution of trials, type of proteindegrader, phase of development, study design, leading industry and non-industryplayers (in terms of number of trials conducted), study focus, targettherapeutic area, key indications, and clinical endpoints.
§ An assessment of therelative experience of key opinion leaders (KOLs) within this domain, (shortlistedbased on their involvement in various clinical studies), featuringdetailed 2X2 matrices (based on the strength and activeness of KOLs), aschematic world map representation (highlighting the geographical locations ofeminent scientists / researchers) and an analysis evaluating the (relative)level of expertise of different KOLs, based on parameters such as number ofpublications, number of citations, participation in clinical trials, number ofaffiliations and strength of professional network (based on informationavailable on ResearchGate).
§ A detailedpublication analysis of more than 210 peer-reviewed, scientific articles thathave been published since 2017, highlighting the research focus within theindustry. It also highlights the key trends observed across the publications,including information on novel protein degraders, potential target proteins,target disease indications, and analysis based on various relevant parameters,such as year of publication, and most popular journals (in terms of numberof articles published in the given time period) within this domain.
§ An analysis of thepartnerships that have been established in the domain, over the period 2014-Q32019, covering research agreements, product / technology licensing agreements,mergers / acquisitions, asset purchase agreements, R&D andcommercialization agreements, IP licensing agreements, clinical trialagreements, product development agreements, and other relevant deals.
§ An analysis of theinvestments made at various stages of development, such as seed financing,venture capital financing, debt financing, grants / awards, capital raised fromIPOs and subsequent offerings, by companies that are engaged in this field.
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ Typeof payment of licensing agreements
§ Upfrontpayments
§ Milestonepayments
§ Type of protein degrader
§ Degronimids
§ PROTACs
§ SARDs/ SERDs
§ SpecificBET and DUB inhibitors
§ Otherprotein degraders
§ Therapeutic area
§ Neurodegenerativedisorders
§ Oncologicaldisorders
§ Othertherapeutic areas
§ Routeof administration
§ Oral
§ Intravenous
§ Otherroutes
§ Keygeographical region
§ NorthAmerica
§ Europe
§ Asia-Pacific
To request a samplepages, please visit this link
KeyQuestions Answered
§ Whatare the prevalent R&D trends related to targeted protein degradation?
§ Whichclinical conditions can be treated using targeted protein degradation-basedtherapeutics?
§ Whatare the most popular proteins being targeted by bifunctional degradermolecules?
§ Whatare the key challenges faced by stakeholders engaged in this domain?
§ Whatare the key technology platforms that leverage the concept of targeted proteindegradation?
§ Whoare the leading industry and non-industry players in this market?
§ Whatare the contributions of big pharma players in this field?
§ Whatare the key geographies where research on targeted protein degradation is beingconducted?
§ Whoare the key investors in this domain?
§ Whoare the key opinion leaders / experts in this field?
§ Whatkind of partnership models are commonly adopted by industry stakeholders?
§ Whatare the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
You may also beinterested in the following titles:
1. DNA-EncodedLibraries: Platforms and Services Market
2. GlobalStem Cells Market: Focus on Clinical Therapies, 2020–2030
Contact Details:
Gaurav Chaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
